Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations

Area of Science:

• Hematology
• Cytogenetics
• Molecular Oncology

Background:

• MECOM rearrangement is a known adverse prognostic factor in myeloid neoplasms.
• Previous studies lacked detailed characterization of MECOM rearrangement mechanisms and frequencies.
• 3q26.2 abnormalities are often associated with MECOM involvement, but require confirmation.

Purpose of the Study:

• To determine the frequency and mechanisms of MECOM rearrangement in myeloid neoplasms.
• To characterize the spectrum of chromosomal aberrations associated with MECOM rearrangement.
• To highlight the importance of confirming MECOM status in cases with 3q26.2 abnormalities.

Main Methods:

• Karyotyping and multiple fluorescence in situ hybridization (FISH) methodologies were used.
• 129 cases with confirmed MECOM rearrangement were analyzed.
• Chromosomal aberrations including translocations, inversions, and insertions were identified.

Main Results:

• MECOM rearrangement was confirmed in 129 myeloid neoplasm cases.
• Translocations (49.6%) and inversions (40.3%) were the predominant mechanisms.
• Specific translocations (e.g., t(3;21), t(2;3), t(3;12)) and inversions (inv(3)(q21q26.2)) were frequently observed.
• Complex karyotypes and atypical FISH patterns were associated with certain rearrangement types.

Conclusions:

• Atypical chromosomal aberrations and mechanisms contribute to MECOM rearrangement.
• Confirmation of MECOM rearrangement is essential for accurate diagnosis and prognosis in myeloid neoplasms with 3q26.2 abnormalities.